Sanofi Wins China Approval for Qfitlia and Cablivi in Rare Blood Disorders
I'm PortAI, I can summarize articles.
Sanofi SA has received approval from China's NMPA for Qfitlia and Cablivi, expanding its rare hematology portfolio. Qfitlia is the first antithrombin-lowering therapy for hemophilia in China, requiring only six injections annually. Cablivi, the first Nanobody medicine approved in China, treats the rare blood disorder aTTP/iTTP. These approvals address unmet needs for chronic bleeding disorders and acute clotting emergencies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments